Jump to content

Search the Community

Showing results for tags 'ANA positive'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


  • The LuPUS Message Board
    • Announcements
    • What is the LuPUS Message Board?
    • A Welcome to New Members
    • User Problems
    • Links
  • Medical
    • Medical News 2003
    • Medical News 2004
    • Medical News 2005
    • Medical News 2006
    • Medical News 2007
    • Medical News 2008
    • Medical News 2009
    • Medical News 2010
    • Medical News 2011
    • Medical News 2012
    • Medical News 2013
    • Medical News 2014
    • Medical News 2015
    • Medical News 2016
    • Medical News 2017
    • Medical News 2018
    • Medical News 2019
    • Medical News 2020
    • Medical News 2021
    • Coronavirus: COVID-19
    • Medication & Therapy
    • Lupus and Pregnancy
    • Sjögren’s syndrome
    • Lymphoedema
    • Marginal Zone Lymphoma
  • Non-Medical
    • LuPUS Message Board
  • Public
    • Guest & Test Messages
    • Free Offers
    • Contributors


  • Admin
  • Admin
  • Changes To My Diet For Health Reasons


There are no results to display.

There are no results to display.

Find results in...

Find results that contain...

Date Created

  • Start


Last Updated

  • Start


Filter by number of...


  • Start





Website URL





Surname (Last or Family name)

First name

Date of Birth




Found 1 result

  1. Benlysta: first targeted lupus treatment 01 November 2011, 9:14am Benlysta (belimumab) is licensed as add-on therapy in patients with autoantibody-positive systemic lupus erythematosus (SLE) who have high disease activity despite standard treatment. Benlysta must be administered in hospital PHARMACOLOGY Belimumab is a monoclonal antibody specific for the soluble human B lymphocyte stimulator protein, BLyS. It inhibits the differentiation of B cells into antibody-producing plasma cells.1 CLINICAL STUDIES Two pivotal randomised trials showed that the addition of belimumab to standard care improves control of disease activity in SLE. BLISS-76 and BLISS-52 enrolled seropositive SLE patients (n=819 and n=865, respectively). In addition to standard treatment, patients received belimumab 10mg/kg or 1mg/kg or placebo by intravenous infusion on days 0, 14 and 28, and every 28 days thereafter.2,3 In both studies, response rates at week 52 (as determined by the SLE Responder Index) were significantly higher in patients treated with the 10mg/kg dose of belimumab than in patients who received placebo. In a pooled analysis of the two studies, the combined response rate was 51% for belimumab 10mg/kg compared with 39% for placebo (p<0.0001).2,3 Belimumab was well tolerated in both studies, with rates of adverse events similar to placebo.2,3 REFERENCES Benlysta Summary of Product Characteristics, July 2011. Furie R et al. Arthritis Rheum 2011, Accepted article; DOI: 10.1002/art.30613. Navarra SV et al. Lancet 2011; 377: 721–31. View Benlysta drug record Further information: GlaxoSmithKline
  • Create New...

Important Information